Matter Bio develops multi-pronged biotechnologies to preserve genome integrity and address aging-related decline. The company’s platform centers on reading mutations, reversing integrated mutations by reintroducing original genetic information, and removing irreparably damaged cells such as cancerous, clonal, and senescent cells. It applies these approaches to study the information theory of aging at a genomic level and to therapeutic development. Matter Bio plans to use recent funding to file an IND and initiate a Phase 1/2a clinical trial in solid cancer. The team includes co-founders George Church, Jan Vijg, and Claudia Gravekamp. Financially, the company closed a $7M Seed round and has grant support from NIH, NCI, and NIEHS.

Total raised

$7M

Funding rounds

1

Latest round

Seed

Latest activity

May 2024